Normalisation is medical misogyny and delays diagnosis
Sharnelle Vella, ABC Radio Melbourne breakfast co-host[/caption]
Mike Stephens, Director, Medicines policy and Programs at the National Aboriginal Community Controlled Health Organisation (NACCHO)[/caption]
Chastina Heck MPS, Chair of the PSA/NACCHO Aboriginal and Torres Strait Islander Pharmacy Practice Community of Specialty Interest (CSI).[/caption]
Philippa Chigeza, pharmacist at Logan Hospital.[/caption]
Stewart Mearns MPS[/caption]
Case scenario
Sarah, a regular customer in your community pharmacy, presents a prescription for riluzole tablets written by a neurologist for her husband David. It has been several months since David, aged 57, has been seen in the pharmacy. Sarah looks visibly upset and not her usual cheerful self.
After reading this article, pharmacists should be able to:
Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5, 3.6 Accreditation number: CAP2410DMBW Accreditation expiry: 30/09/2027 |
Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.
Introduction
Motor neurone disease (MND) is a group of progressive, degenerative disorders of the motor neurones.1 Motor neurones are nerve cells which control the muscles that enable movement, speech, breathing and swallowing, and their degeneration results in muscle weakness and atrophy.1–3
Patients diagnosed with MND have an average survival time of 2.5 years after diagnosis and usually die of respiratory failure.1–3 The initial symptoms, rate and pattern of disease progression and survival times vary between p
THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.
